Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02458313 · ClinicalTrials.gov registry record · Phase 1
Nicotinic Agonist Effects on BMI and Neuronal Response
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT02458313 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 61 participants.
The verdict
NCT02458313, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
Obesity is a serious and growing health problem in the United States. Obesity is associated with health problems such as type-2 diabetes and cardiovascular disease, leading to decreased quality of life and increased mortality. Given the health and quality-of-life effects of obesity, developing effective treatments clearly is an important goal. This study plans to learn more about the effects of an investigational new drug (DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine)) and its effects on obesity. The study drug has similar effects to nicotine. Since nicotine has been found to affect appetite, the investigators are interested in studying effects of the study drug, which has some similarities to nicotine, on how your brain responds to such things as pictures of food. The study drug has not been approved by the Food and Drug Administration (FDA), and is considered experimental.
Interventions
- OTHER Placebo
- DRUG DMXB-A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2016-04-14 |
| Est. Completion | 2021-12-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02458313
The ClinicalTrials.gov registry entry for NCT02458313 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02458313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02458313 about?
NCT02458313 is a clinical study titled "Nicotinic Agonist Effects on BMI and Neuronal Response". Obesity is a serious and growing health problem in the United States. Obesity is associated with health problems such as type-2 diabetes and cardiovascular disease, leading to decreased quality of life and increased mortality. Given the health and quality-of-life effects of obesity, developing effec...
What is the current status of trial NCT02458313?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2016-04-14. Estimated completion is 2021-12-13.
What interventions are being tested in trial NCT02458313?
The interventions under investigation include: Placebo (OTHER), DMXB-A (DRUG).
Who is sponsoring clinical trial NCT02458313?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.